The Conception and Production of Conjugate Vaccines Using Recombinant DNA Technology - Recombinant technology can be used to produce conjugate vaccines in a bacterial expression system. - BioPharm


The Conception and Production of Conjugate Vaccines Using Recombinant DNA Technology
Recombinant technology can be used to produce conjugate vaccines in a bacterial expression system.

BioPharm International
Volume 25, Issue 1, pp. 28-32


The process to create new and efficacious bioconjugate vaccines in a cost-effective and efficient manner has potential, but what is required is proof that such vaccines can be manufactured in commercial quantities, and that the vaccines produced are safe and effective. The following are examples that demonstrate the potential of in vivo bioconjugate technology:

A bioconjugate against Shigella sp. was produced under GMP conditions and tested for the first time in humans. Shigella is an important pathogen responsible for serious diarrhea and dysentery, so a vaccine to prevent infection in the emerging nations where it is present, as well as a vaccine for travellers, would provide a significant public health benefit. No vaccine exists for Shigella, despite ongoing research in many laboratories for several years. Attempts at vaccine development, both conjugate and live-attenuated bacteria, showed modest immunogenicity (8–11). Moreover, the technical hurdles to producing a conjugate vaccine with chemistry-based methods are very high. The bioconjugate produced against the serotype, Shigella dysenteriae, was tested in 40 healthy volunteers and found to be well tolerated. Importantly, the vaccine demonstrated a significant immunogenic response, and these immunogenicity data compare favorably to previous candidate vaccines tested against this pathogen. This promising Phase I data provide clinical proof-of-concept that the bioconjugate produced under GMP conditions by an recombinant DNA technology is safe and induces an immunogenic response in human.

The technology has been also applied for the development of a bioconjugate against Staphylococcus aureus. Nosocomial S. aureus infections represent up to 50% of all hospital infections. Moreover, methicillin-resistant S. aureus (MRSA) rates continue to increase dramatically. Despite significant research efforts undertaken by academic and pharmaceutical laboratories to develop a successful vaccine, there has been no recorded sustained effectiveness against S. aureus has been generated by the experimental vaccines tested (12, 13). More recently, the DNA recombinant in vivo technology was able to conjugate, for the first time, the main polysaccharides of S. aureus to a selected protein carrier of the same pathogen (i.e, antigen protein of S. aureus). This bioconjugate vaccine has been tested in animals and produced functional antibodies inducing protection in mice bacteremia and lethal pneumonia models (14). Although early, these results are promising considering recent clinical trial failures of S. Aureus candidate vaccines. The combination of polysaccharide and protein antigen against the pathogen will increase the immunogenicity of the vaccine at various stages and pathways of the infection, thus enhancing the possibility of protection.

These data demonstrate that this in vivo technology is a feasible approach for developing vaccines against challenging pathogens and offers the promise of improved efficiency in general.


Antibacterial conjugate vaccines have become important tools for the public-health community to prevent serious bacterial infections. However, the complex development and manufacturing process has limited the potential of this important class of vaccine. This article describes a new in vivo process that incorporates a well-understood recombinant DNA technology in E. coli to manufacture bioconjugate vaccines. The process has demonstrated proof-of-concept in more than one bacterial pathogen, including a first-in-man study. Research is currently in progress to develop additional vaccine candidates and advance them into late-stage clinical trials.

Veronica Gambillara PhD is director of clinical and regulatory affairs at GlycoVacyn, Schlieren Switzerland,


1. Datamonitor, Pneumococcal and Meningococcal Vaccines: Market Forecast (Datamonitor, 2010).

2. O.T. Avery and W. F. Goebel, J. Exp. Med. 50 (4), 521–533 (1929).

3. M. Kowarik et al., EMBO J. 25 (9), 1957–1966 (2006).

4. M. Wacker et. al., Science 298 (5599), 1790–1793 (2002).

5. T.D. Bugg and P. E. Brandish, FEMS Microbiol. Lett. 119 (3), 255–262 (1994).

6. M.F. Feldman et al., Proc. Natl. Acad. Sci. 102 (8), 3016–3021 (2005).

7. M. Wacker et al., Proc. Natl. Acad. Sci. 103 (18), 7088–7093 (2006).

8. J.B. Robbins, C. Chu, and R. Schneerson, Clin. Infect. Dis. 15 (2), 346–361 (1992).

9. J.B. Robbins et al., Proc. Natl. Acad. Sci. 106 (19), 7974–7978 (2009).

10. M.M. Levine et al., J. Infect. Dis. 127 (3), 261–270 (1973).

11. M.M. Levine et al., N. Engl. J. Med. 288 (22), 1169–1171 (1973).

12. J.C. Lee, Curr. Infect. Dis. Rep. 3 (6), 517–524 (2001).

13. G.L. Archer, Clin Infect Dis 26, 1179–1181 (1998).

14. J.C. Lee et al., presentation at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago, IL, 2011).

blog comments powered by Disqus



Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here